WO1999065513A3 - Pharmaceutical compositions for the treatment of helicobacter pylori-associated disorders - Google Patents

Pharmaceutical compositions for the treatment of helicobacter pylori-associated disorders Download PDF

Info

Publication number
WO1999065513A3
WO1999065513A3 PCT/IL1999/000335 IL9900335W WO9965513A3 WO 1999065513 A3 WO1999065513 A3 WO 1999065513A3 IL 9900335 W IL9900335 W IL 9900335W WO 9965513 A3 WO9965513 A3 WO 9965513A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical compositions
pylori
associated disorders
helicobacter pylori
treatment
Prior art date
Application number
PCT/IL1999/000335
Other languages
French (fr)
Other versions
WO1999065513A2 (en
Inventor
Michal Y Chowers
Yehuda Chowers
Original Assignee
Michal Y Chowers
Yehuda Chowers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michal Y Chowers, Yehuda Chowers filed Critical Michal Y Chowers
Priority to AU43882/99A priority Critical patent/AU768612B2/en
Priority to AT99926719T priority patent/ATE263572T1/en
Priority to CA002331834A priority patent/CA2331834A1/en
Priority to JP2000554391A priority patent/JP2003522105A/en
Priority to EP99926719A priority patent/EP1087783B1/en
Priority to DE69916273T priority patent/DE69916273T2/en
Publication of WO1999065513A2 publication Critical patent/WO1999065513A2/en
Publication of WO1999065513A3 publication Critical patent/WO1999065513A3/en
Priority to US09/738,948 priority patent/US6815414B2/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2207—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/595—Gastrins; Cholecystokinins [CCK]

Abstract

The invention relates to pharmaceutical compositions and methods for treating and/or preventing Helicobacter pylori-associated disorders, particularly disorders of the gastrointestinal tract. The pharmaceutical compositions comprise as active ingredient a therapeutically effective amount of a compound which inhibits the growth-enhancing effect of gastrin on H. pylori. The active ingredient may specifically be a compound which is capable of inhibiting gastrin uptake by H. pylori, and/or which is an antagonist of the human or H. pylori gastrin receptor.
PCT/IL1999/000335 1998-06-18 1999-06-17 Pharmaceutical compositions for the treatment of helicobacter pylori-associated disorders WO1999065513A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU43882/99A AU768612B2 (en) 1998-06-18 1999-06-17 Pharmaceutical compositions for the treatment of (helicobacter pylori)-associated disorders
AT99926719T ATE263572T1 (en) 1998-06-18 1999-06-17 USE OF GASTRIN FRAGMENTS OR SYTHETICAL ANALOGUES OF GASTRIN FOR THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF HELICOBACTER PYLORI ASSOCIATED DISORDERS
CA002331834A CA2331834A1 (en) 1998-06-18 1999-06-17 Pharmaceutical compositions for the treatment of helicobacter pylori-associated disorders
JP2000554391A JP2003522105A (en) 1998-06-18 1999-06-17 Pharmaceutical composition for treating Helicobacter pylori-related diseases
EP99926719A EP1087783B1 (en) 1998-06-18 1999-06-17 Use of gastrin fragments or synthetic analogs of gastrin for the manufacture of a medicament for the treatment of helicobacter pylori-associated disorders
DE69916273T DE69916273T2 (en) 1998-06-18 1999-06-17 USE OF GASTRIN FRAGMENTS OR SYNTHETIC ANALOGS OF GASTRIN FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING HELICOBACTER PYLORI-ASSOCIATED DISORDER
US09/738,948 US6815414B2 (en) 1998-06-18 2000-12-15 Pharmaceutical compositions for the treatment of helicobacter pylori-associated disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8977098P 1998-06-18 1998-06-18
US60/089,770 1998-06-18
US14719599P 1999-05-20 1999-05-20
US60/147,195 1999-05-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/738,948 Continuation US6815414B2 (en) 1998-06-18 2000-12-15 Pharmaceutical compositions for the treatment of helicobacter pylori-associated disorders

Publications (2)

Publication Number Publication Date
WO1999065513A2 WO1999065513A2 (en) 1999-12-23
WO1999065513A3 true WO1999065513A3 (en) 2000-03-02

Family

ID=26780929

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL1999/000335 WO1999065513A2 (en) 1998-06-18 1999-06-17 Pharmaceutical compositions for the treatment of helicobacter pylori-associated disorders

Country Status (8)

Country Link
US (1) US6815414B2 (en)
EP (1) EP1087783B1 (en)
JP (1) JP2003522105A (en)
AT (1) ATE263572T1 (en)
AU (1) AU768612B2 (en)
CA (1) CA2331834A1 (en)
DE (1) DE69916273T2 (en)
WO (1) WO1999065513A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040001842A1 (en) * 1997-05-12 2004-01-01 Dov Michaeli Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors
JP2002515458A (en) * 1998-05-15 2002-05-28 アフトン・コーポレーシヨン Prevention and treatment of hypergastrinemia
WO2001035899A2 (en) * 1999-11-19 2001-05-25 Axxima Pharmaceuticals Ag Inhibitors of helicobacter pylori induced gastrointestinal diseases
US6849409B2 (en) 2000-10-16 2005-02-01 Axxima Pharmaceuticals Ag Cellular kinases involved in Cytomegalovirus infection and their inhibition
AU2002252456A1 (en) 2001-03-23 2002-10-08 Aphton Corporation Combination treatment of pancreatic cancer
US20090191232A1 (en) 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
JP2004536835A (en) * 2001-07-09 2004-12-09 アフトン コーポレーション Treatment and prevention of cancerous and precancerous conditions of the liver, lungs and esophagus
US6810583B2 (en) * 2001-08-07 2004-11-02 International Business Machines Corporation Coupling of conductive vias to complex power-signal substructures
IL152289A0 (en) * 2002-10-14 2003-05-29 Vectabiotics Ltd Method and composition for inhibiting h.pylori infection in a mammalian tissue
EP1608984A2 (en) * 2003-03-28 2005-12-28 Aphton Corporation Gastrin hormone immunoassays
CN101048659B (en) 2004-09-22 2013-03-13 受体生物技术公司 Monoclonal antibodies to progastrin
US20060121031A1 (en) * 2004-12-07 2006-06-08 Mckenzie Brent S Relay vaccine
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
WO2008012621A2 (en) 2006-07-25 2008-01-31 Vecta, Ltd. Compositions and meth0ds for inhibiting gastric acide secretion using derivatives of small dicarboxylic acids in combination with ppi
US9532739B2 (en) 2011-06-14 2017-01-03 Gravitas Medical, Inc. Methods and apparatus for guiding medical care based on detected gastric function
US9700514B1 (en) 2014-08-20 2017-07-11 Darren Rubin Single solid oral dosage forms for treating Helicobacter pylori infection and duodenal ulcer disease
CA3066756A1 (en) 2017-06-15 2018-12-20 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
US11263510B2 (en) * 2020-07-15 2022-03-01 GM Global Technology Operations LLC Method for performing measurements of dendritic structures for all magnifications and camera resolutions of microscopes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09183764A (en) * 1995-12-28 1997-07-15 Roussel Morishita Kk N-benzoylproline ester derivative

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1204430B (en) * 1986-01-10 1989-03-01 Alfio Bertolini PHARMACEUTICAL COMPOSITIONS INCLUDING PEPTIDES OF THE COLECISTOKININA-CERULINA GROUP FOR THE THERAPEUTIC TREATMENT OF SHOCK STATES AND RESPIRATORY AND CARDIOCIRCULATORY INSUFFICIENCY
ATE114160T1 (en) * 1989-01-24 1994-12-15 Aphton Corp IMMUNOGENIC COMPOSITIONS AGAINST GASTRIN PEPTIDES.
US4997950A (en) * 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09183764A (en) * 1995-12-28 1997-07-15 Roussel Morishita Kk N-benzoylproline ester derivative

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199738, Derwent World Patents Index; Class B03, AN 1997-410809, XP002126333 *
K. YAMASHITA ET AL.: "INHIBITORY EFFECT OF SOMATOSTATIN ON HELICOBACTER PYLORI PROLIFERATION IN VITRO.", GASTROENTEROLOGY, vol. 115, no. 5, November 1998 (1998-11-01), NEW YORK, US, pages 1123 - 1130, XP000857858 *

Also Published As

Publication number Publication date
US6815414B2 (en) 2004-11-09
WO1999065513A2 (en) 1999-12-23
EP1087783A2 (en) 2001-04-04
ATE263572T1 (en) 2004-04-15
JP2003522105A (en) 2003-07-22
AU768612B2 (en) 2003-12-18
CA2331834A1 (en) 1999-12-23
DE69916273D1 (en) 2004-05-13
DE69916273T2 (en) 2005-05-19
AU4388299A (en) 2000-01-05
EP1087783B1 (en) 2004-04-07
US20010020005A1 (en) 2001-09-06

Similar Documents

Publication Publication Date Title
WO1999065513A3 (en) Pharmaceutical compositions for the treatment of helicobacter pylori-associated disorders
WO2002046129A3 (en) Inhibitors of histone deacetylase
WO2002047712A3 (en) Peptide yy and peptide yy agonists for treatment of metabolic disorders
WO2003057698A3 (en) Spiroazacyclic compounds as monoamine receptor modulators
WO2001022953A3 (en) Use of retigabin for treating neuropathic pain
AU2001260400A1 (en) Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders
JO2372B1 (en) Prodrugs of 4-phenyl-pyridine derivatives
WO2003097608A3 (en) Opioid and opioid-like compounds and uses thereof
WO2004021989A3 (en) Imidazolopyridines and methods of making and using the same
WO2002100347A3 (en) Prodrugs of gaba analogs, compositions and uses thereof
WO1999044581A3 (en) Pharmaceutical composition of topiramate
CA2370030A1 (en) Sodium channel blocker compositions and the use thereof
HK1080456A1 (en) N-substituted hydromorphones and the use thereof
EP1247456A3 (en) Palatable pharmaceutical compositions for companion animals
WO2000072837A3 (en) Methods and compositions for the treatment of neuroleptic and related disorders using sertindole derivatives
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
WO2003037368A3 (en) Smad7 inhibitors for the treatment of cns diseases
CA2378428A1 (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
EP1413201A3 (en) Use of neuronal sodium channel antagonists for the control of ectoparasites in homeothermic animals
WO2006134492A3 (en) Acarbose methods and formulations for treating chronic constipation
MY126117A (en) Pharmaceutical compositions
WO2000051582A3 (en) Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
WO2006015970A3 (en) Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic
CA2441192A1 (en) The use of lysine for the prevention or treatment of stress-induced diseases
WO2000048446A3 (en) Use of antagonists of pg-e for the treatment of neuropathic pain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 09738948

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2331834

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1999926719

Country of ref document: EP

Ref document number: 43882/99

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1999926719

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 43882/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999926719

Country of ref document: EP